The ACE I/D Polymorphism and Human Physical Performance

The D allele of the angiotensin-converting enzyme (ACE) I/D polymorphism is associated with elevated levels of serum and tissue ACE, increased production of the vasopressor angiotensin II and a reduction in the half-life of the vasodilator bradykinin. Several cardiac and renal conditions appear to have a worse prognosis in subjects homozygous for the D allele, whereas the I allele has been associated with enhanced endurance performance in elite distance runners, rowers and mountaineers. The nature of the gene-environment interaction between ACE I/D polymorphisms and physical training, an overview of recent findings and a discussion of possible underlying mechanisms is the subject of this review.

[1]  R. Mayfield,et al.  Tissue kallikrein and bradykinin do not have direct insulin-like actions on skeletal muscle glucose utilization. , 1987, Biological Chemistry Hoppe-Seyler.

[2]  G. Ferretti,et al.  Physiological profile of world-class high-altitude climbers. , 1986, Journal of applied physiology.

[3]  D R Bassett,et al.  Limiting factors for maximum oxygen uptake and determinants of endurance performance. , 2000, Medicine and science in sports and exercise.

[4]  Jimmy D Bell,et al.  Human gene for physical performance , 1998, Nature.

[5]  N. Iwai,et al.  Expression of angiotensin converting enzyme and chymase in human atria , 1997, Journal of hypertension.

[6]  F. Cobb,et al.  Skeletal muscle biochemistry and histology in ambulatory patients with long-term heart failure. , 1990, Circulation.

[7]  C. Mamotte,et al.  Elite athletes and the gene for angiotensin-converting enzyme. , 1999, Journal of applied physiology.

[8]  R. Minshall,et al.  Bradykinin B2 Receptors on Skeletal Muscle are Coupled to Inositol 1,4,5-Trisphosphate Formation , 1996, Diabetes.

[9]  Jimmy D Bell,et al.  Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical training , 1999, The Lancet.

[10]  G S Krahenbuhl,et al.  Running economy and distance running performance of highly trained athletes. , 1980, Medicine and science in sports and exercise.

[11]  G. Radda,et al.  Abnormalities in exercising skeletal muscle in congestive heart failure can be explained in terms of decreased mitochondrial ATP synthesis, reduced metabolic efficiency, and increased glycogenolysis. , 1996, Heart.

[12]  W. Linz,et al.  Role of Kinins in the Pathophysiology of Myocardial Ischemia: In Vitro and In Vivo Studies , 1996, Diabetes.

[13]  G. Pontone,et al.  Synergistic efficacy of enalapril and losartan on exercise performance and oxygen consumption at peak exercise in congestive heart failure. , 1999, The American journal of cardiology.

[14]  J. Karjalainen,et al.  Angiotensinogen gene M235T polymorphism predicts left ventricular hypertrophy in endurance athletes. , 1999, Journal of the American College of Cardiology.

[15]  R. Ferrell,et al.  VO2 max is associated with ACE genotype in postmenopausal women. , 1998, Journal of applied physiology.

[16]  R. Schifman,et al.  Insulin-like activity of bradykinin on amino acid balances across the human forearm. , 1980, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

[17]  C. Bouchard,et al.  No association between the angiotensin-converting enzyme ID polymorphism and elite endurance athlete status. , 2000, Journal of applied physiology.

[18]  Vicotor J Dzau,et al.  Circulating versus local renin‐angiotensin system in cardiovascular homeostasis , 1988, Circulation.

[19]  J H Wilmore,et al.  Angiotensin-converting enzyme ID polymorphism and fitness phenotype in the HERITAGE Family Study. , 2000, Journal of applied physiology.

[20]  M. Brink,et al.  Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. , 1996, The Journal of clinical investigation.

[21]  H. Mehnert,et al.  Dose-dependent effect of bradykinin on muscular blood flow and glucose uptake in man. , 1983, Hoppe-Seyler´s Zeitschrift für physiologische Chemie.

[22]  K. Williams,et al.  Three-dimensional structure of the ion-coupled transport protein NhaA , 2000, Nature.

[23]  H. E. Montgomery,et al.  Physiology: The ACE gene and muscle performance , 2000, Nature.

[24]  J. Holloszy,et al.  Bradykinin does not mediate activation of glucose transport by muscle contraction. , 1986, Journal of applied physiology.

[25]  H. Schunkert,et al.  Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. , 1995, Circulation.

[26]  P. Cerretelli,et al.  II. Morphological Adaptations of Human Skeletal Muscle to Chronic Hypoxia* , 1990, International journal of sports medicine.

[27]  R. Minshall,et al.  Kininase II-Type Enzymes: Their Putative Role in Muscle Energy Metabolism , 1996, Diabetes.

[28]  Bing Yu,et al.  Elite endurance athletes and the ACE I allele – the role of genes in athletic performance , 1998, Human Genetics.

[29]  W. Linz,et al.  Beneficial effects of the converting enzyme inhibitor, ramipril, in ischemic rat hearts. , 1986, Journal of cardiovascular pharmacology.

[30]  L. Zisman Inhibiting tissue angiotensin-converting enzyme: a pound of flesh without the blood? , 1998, Circulation.

[31]  A. Morris,et al.  DD angiotensin-converting enzyme gene polymorphism is associated with endothelial dysfunction in normal humans. , 1999, Hypertension.

[32]  K. Swedberg,et al.  Angiotensin-converting enzyme gene expression in skeletal muscle in patients with chronic heart failure. , 1998, Journal of cardiac failure.

[33]  H. Predel,et al.  ACE inhibition and physical exercise: studies on physical work capacity, energy metabolism, and maximum oxygen uptake in well-trained, healthy subjects. , 1994, Journal of cardiovascular pharmacology.

[34]  E. Coyle,et al.  Cycling efficiency is related to the percentage of type I muscle fibers. , 1992, Medicine and science in sports and exercise.

[35]  P Corvol,et al.  An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. , 1990, The Journal of clinical investigation.

[36]  N. Brown,et al.  ACE insertion/deletion genotype affects bradykinin metabolism. , 1998, Journal of cardiovascular pharmacology.

[37]  C. Bouchard,et al.  Individual differences in the response to regular exercise. , 1995, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[38]  J H Wilmore,et al.  Familial resemblance for VO2max in the sedentary state: the HERITAGE family study. , 1998, Medicine and science in sports and exercise.

[39]  D. Hoefnagel,et al.  Partial lipodystrophy and familial C3 deficiency. , 1980, Human heredity.

[40]  P. Game,et al.  The expression and localisation of the angiotensin-converting enzyme mRNA in human adipose tissue. , 1994, Blood pressure.

[41]  H Hemingway,et al.  Human angiotensin I-converting enzyme gene and endurance performance. , 1999, Journal of applied physiology.

[42]  T J Walters,et al.  Determinants of endurance in well-trained cyclists. , 1988, Journal of applied physiology.

[43]  P. Shetty,et al.  Net mechanical efficiency during stepping in chronically energy-deficient human subjects. , 1992, Annals of human biology.

[44]  Increased muscular efficiency during lactation in Colombian women , 1998, European Journal of Clinical Nutrition.

[45]  G. Brooks,et al.  Muscular efficiency during steady-rate exercise: effects of speed and work rate. , 1975, Journal of applied physiology.

[46]  N Risch,et al.  The Future of Genetic Studies of Complex Human Diseases , 1996, Science.

[47]  P. Agostoni,et al.  Angiotensin‐converting enzyme inhibition facilitates alveolar‐capillary gas transfer and improves ventilation‐perfusion coupling in patients with left ventricular dysfunction , 1999, Clinical pharmacology and therapeutics.

[48]  C. Bouchard,et al.  Aerobic performance in brothers, dizygotic and monozygotic twins. , 1986, Medicine and science in sports and exercise.

[49]  J. Ménard,et al.  Vascular angiotensin-converting enzyme expression regulates local angiotensin II. , 1997, Hypertension.

[50]  A. Minetti,et al.  IV. Oxygen Transport System Before and After Exposure to Chronic Hypoxia , 1990, International journal of sports medicine.

[51]  W. Linz,et al.  Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. , 1990, European journal of pharmacology.